Abstract
There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Current Vascular Pharmacology
Title: Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Volume: 8 Issue: 4
Author(s): Elli Stefanadi, Dimitris Tousoulis, Emmanuel S. Androulakis, Nikolaos Papageorgiou, Marietta Charakida, Gerasimos Siasos, Costas Tsioufis and Christodoulos Stefanadis
Affiliation:
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Abstract: There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Export Options
About this article
Cite this article as:
Stefanadi Elli, Tousoulis Dimitris, S. Androulakis Emmanuel, Papageorgiou Nikolaos, Charakida Marietta, Siasos Gerasimos, Tsioufis Costas and Stefanadis Christodoulos, Inflammatory Markers in Essential Hypertension: Potential Clinical Implications, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330870
DOI https://dx.doi.org/10.2174/157016110791330870 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Artery Stenosis: Current Perspectives on Imaging and Endovascular Management
Current Hypertension Reviews Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Patent Review
Combinatorial Chemistry & High Throughput Screening Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders NINJ2 Gene Polymorphisms and Susceptibility to Ischemic Stroke: An Updated Meta-Analysis
Current Neurovascular Research Primary Vesicoureteric Reflux and Reflux Nephropathy - New Insights
Current Pediatric Reviews Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Precision Medicine in the Renin-Angiotensin System: Therapeutic Targets and Biological Variability
Current Drug Targets Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Beta-Blocking Agents and Electroconvulsive Therapy
Current Drug Therapy Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs
Current Pharmaceutical Design Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Current Vascular Pharmacology